Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Jeffrey W Eaton,Nicolas A Menzies,John Stover,Valentina Cambiano,Leonid Chindelevitch,Anne Cori,Jan A C Hontelez,Salal Humair,Cliff C Kerr,Daniel J Klein,Sharmistha Mishra,Kate M Mitchell,Brooke E Nichols,Peter Vickerman,Roel Bakker,Till Bärnighausen,Anna Bershteyn,David E Bloom,Marie-Claude Boily,Stewart T Chang,Ted Cohen,Peter J Dodd,Christophe Fraser,Chaitra Gopalappa,Jens Lundgren,Natasha K Martin,Evelinn Mikkelsen,Elisa Mountain,Quang D Pham,Michael Pickles,Andrew Phillips,Lucy Platt,Carel Pretorius,Holly J Prudden,Joshua A Salomon,David A M C van de Vijver,Sake J de Vlas,Bradley G Wagner,Richard G White,David P Wilson,Lei Zhang,John Blandford,Gesine Meyer-Rath,Michelle Remme,Paul Revill,Nalinee Sangrujee,Fern Terris-Prestholt,Meg Doherty,Nathan Shaffer,Philippa J Easterbrook,Gottfried Hirnschall,Timothy B Hallett
DOI: https://doi.org/10.1016/s2214-109x(13)70172-4
2013-01-01
Abstract:BACKGROUND:New WHO guidelines recommend ART initiation for HIV-positive persons with CD4 cell counts ≤500 cells/µL, a higher threshold than was previously recommended. Country decision makers must consider whether to further expand ART eligibility accordingly.
METHODS:We used multiple independent mathematical models in four settings-South Africa, Zambia, India, and Vietnam-to evaluate the potential health impact, costs, and cost-effectiveness of different adult ART eligibility criteria under scenarios of current and expanded treatment coverage, with results projected over 20 years. Analyses considered extending eligibility to include individuals with CD4 ≤500 cells/µL or all HIV-positive adults, compared to the previous recommendation of initiation with CD4 ≤350 cells/µL. We assessed costs from a health system perspective, and calculated the incremental cost per DALY averted ($/DALY) to compare competing strategies. Strategies were considered 'very cost-effective' if the $/DALY was less than the country's per capita gross domestic product (GDP; South Africa: $8040, Zambia: $1425, India: $1489, Vietnam: $1407) and 'cost-effective' if $/DALY was less than three times per capita GDP.
FINDINGS:In South Africa, the cost per DALY averted of extending ART eligibility to CD4 ≤500 cells/µL ranged from $237 to $1691/DALY compared to 2010 guidelines; in Zambia, expanded eligibility ranged from improving health outcomes while reducing costs (i.e. dominating current guidelines) to $749/DALY. Results were similar in scenarios with substantially expanded treatment access and for expanding eligibility to all HIV-positive adults. Expanding treatment coverage in the general population was therefore found to be cost-effective. In India, eligibility for all HIV-positive persons ranged from $131 to $241/DALY and in Vietnam eligibility for CD4 ≤500 cells/µL cost $290/DALY. In concentrated epidemics, expanded access among key populations was also cost-effective.
INTERPRETATION:Earlier ART eligibility is estimated to be very cost-effective in low- and middle-income settings, although these questions should be revisited as further information becomes available. Scaling-up ART should be considered among other high-priority health interventions competing for health budgets.
FUNDING:The Bill and Melinda Gates Foundation and World Health Organization.